Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2026-01-01 @ 12:13 AM
Study NCT ID:
NCT02514694
Status:
COMPLETED
Last Update Posted:
2017-05-03
First Post:
2015-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
LEO 32731 - A Phase I Study in Healthy Subjects
Sponsor:
LEO Pharma
Organization:
Study Overview
Official Title:
LEO 32731 - A Phase I, Single-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis. The aim (s) of this Study are to determine:
* The safety and tolerability of the Study Drug and any side effects that might be associated with it
* The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.
* The safety and tolerability of the Study Drug and any side effects that might be associated with it
* The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: